PR062/#686  First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

• Published in: International journal of gynecological cancer Vol. 33; no. Suppl 4; p. A66
• Main Authors: Konecny, Gottfried, Hendrickson, Andrea Wahner, Winterhoff, Boris, Chander, Cinthiya, Bilic, Sanela, Davenport, Simon, Chung, Adrine, Miller, Lei-Lani, Press, Michael, Letrent, Stephen, Slamon, Dennis
• Format: Journal Article
• Language: English
• Published: Oxford BMJ Publishing Group Ltd 07.11.2023; BMJ Publishing Group LTD
• Subjects: Featured Posters: Poster Rounds with the Professors; Ovarian cancer; Tumors

IntroductionCLDN6 is highly expressed in multiple cancers with little to no expression in normal tissues, thus is an ideal target to explore a novel therapeutic. TORL-1–23 is first-in-class ADC targeting the tumor-specific antigen CLDN6.MethodsA first in human, 2-part study (TORL123–001 [NCT05103683...